Abstract 754P
Background
Posterior mediastinal neuroblastoma is a rare neoplasm representing 20% of all neuroblastomas. The impact of clinical features on the prognosis is still unknown, and very limited data are available in the literature. So, we aimed to study the clinicopathological features of that rare subtype for a better understanding of its nature and to provide updated evidence to the literature.
Methods
Data were extracted from the SEER database for posterior mediastinal neuroblastoma patients. Survival session was used to calculate the overall survival (OS) and cause-specific survival (CSS). Patients were subgrouped according to the treatment modality: Primary chemotherapy, surgery with no systemic therapy, and surgery with systemic therapy. Kaplan-Meier curve and Log-Rank test were used for survival analysis.
Results
Out of 135 cases with posterior mediastinal neuroblastoma, with an OS of 92.8% and a CSS of 93.5%, 69 were males. The CSS in males was 93.9%, while in females, it was 91.3%. Males and females had quite similar 5-year OS (93.9% and 91.3%, P=0.67). Caucasians had quite similar OS compared to African-Americans (92.1% and 90.4%, P=0.6). Tumor size less than 4 cm had a CSS of 100%, while larger than 4 cm had a CSS of 92.1% (P=0.79). Patients younger than 1 year had a CSS of 96.8%, while older than 1 year had a CSS of 90.2% (P=0.06). Surgery with no systemic therapy had quite similar OS to surgery with systemic chemotherapy (97.8% and 94.6%). However, both modalities had a survival benefit of 30% compared to primary chemotherapy (72.0%, P=0.02). Performing Cox-regression analysis for age, sex, year of diagnosis, race, radiotherapy, chemotherapy, time from diagnosis to treatment, grade, lymph nodes number showed no association with the survival outcome (P>0.05).
Conclusions
Surgery with systemic chemotherapy showed no privilege over surgery with no systemic therapy on the survival outcome of posterior mediastinal neuroblastoma patients. So, the results highlight surgical excision as the modality of choice to avoid chemotherapy complications for better management outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.